Search results for "Cutaneous"

showing 10 items of 1022 documents

THU0413 New Formulation with Potential for the Prevention and Treatment of Osteoporosis and Osteoarthritis

2013

Background Osteoarthritis (OA) is a multidimensional disease that affects all anatomical joint structures, particularly cartilage, synovium and subchondral bone. In turn, osteoporosis (OP) is a skeletal disorder characterized by a compromised bone strength which substantially increases the risk of fracture. Both are common disorders which affect quality of life in elderly. Despite this, there is not any drug at the moment for the simultaneous prevention and treatment of osteoporosis and osteoarthritis. Objectives The aim of this study was to investigate the effect of a new formulation in a combined rat model of OP and OA. The formulation (BIS076) contains Vitamin D3, Hydroxyapatite as a sou…

medicine.medical_specialtybusiness.industryButorphanolCartilageImmunologyOsteoporosisUrologyOsteoarthritismedicine.diseaseGeneral Biochemistry Genetics and Molecular BiologySurgerySubcutaneous injectionmedicine.anatomical_structureRheumatologySkeletal disorderSynovitisOvariectomized ratImmunology and AllergyMedicinebusinessmedicine.drugAnnals of the Rheumatic Diseases
researchProduct

Reperfusion Treatment in an Acute Myocardial Infarction in Patients Older Than 75 Years. Do We Need a Randomized Controlled Trial?

2005

Fibrinolytic therapy in ST-segment elevation acute myocardial infarction (AMI) constitutes one of the most important advances in cardiology in the last 25 years and has influenced the management and evolution of patients as much as the first coronary care units did. The most important limitations of fibrinolytics are the presence of absolute or relative contraindications to their administration in ≤25% of patients, their limited capacity to restore adequate coronary flow and the risk of inducing cerebral hemorrhage. They are at their most efficient in the first 2 hours’ evolution of AMI but lose their efficacy thereafter. 1 Consequently, treatment must be initiated as early as possible and …

medicine.medical_specialtybusiness.industryCardiogenic shockmedicine.medical_treatmentPercutaneous coronary interventionGeneral MedicineOdds ratioThrombolysismedicine.diseaselaw.inventionSurgeryRandomized controlled triallawInternal medicineConventional PCImedicineCardiologycardiovascular diseasesMyocardial infarctionbusinessStrokeRevista Española de Cardiología (English Edition)
researchProduct

P2482Prediction of in-hospital cardiogenic shock development among patients with ST-segment elevation myocardial infarction treated by primary percut…

2018

medicine.medical_specialtybusiness.industryCardiogenic shockmedicine.medical_treatmentPercutaneous coronary interventionmedicine.diseaseElevation (emotion)Internal medicineCardiologyMedicineST segmentMyocardial infarctionCardiology and Cardiovascular MedicinebusinessEuropean Heart Journal
researchProduct

Long-Term Clinical Outcomes After Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting for Ostial/Midshaft Lesions in Unprotecte…

2014

Objectives The aim of this study was to report the long-term clinical outcomes after percutaneous coronary intervention (PCI) with drug-eluting stents (DES) versus coronary artery bypass grafting (CABG) for ostial/midshaft lesions in an unprotected left main coronary artery (ULMCA). Background Data regarding outcomes in these patients are limited. Methods Of a total of 2,775 patients enrolled in the DELTA multinational registry, 856 patients with isolated ostial/midshaft lesions in an ULMCA treated by PCI with DES (n = 482) or CABG (n = 374) were analyzed. Results At a median follow-up period of 1,293 days, there were no significant differences in the propensity score-adjusted analyses for …

medicine.medical_specialtybusiness.industryIncidence (epidemiology)medicine.medical_treatmentHazard ratioPercutaneous coronary interventionEuroSCOREmedicine.diseaseConfidence intervalSurgerymedicine.anatomical_structureInternal medicineConventional PCImedicineCardiologyMyocardial infarctionbusinessCardiology and Cardiovascular MedicineArteryJACC-Cardiovascular interventions
researchProduct

Innovative Managed Care May Be Related to Improved Prognosis for Acute Myocardial Infarction Survivors

2021

Background: Mortality following discharge in myocardial infarction survivors remains high. Therefore, we compared outcomes in myocardial infarction survivors participating and not participating in a novel, nationwide managed care program for myocardial infarction survivors in Poland. Methods: We used public databases. We included all patients hospitalized due to acute myocardial infarction in Poland between October 1, 2017 and December 31, 2018. We excluded from the analysis all patients aged <18 years as well as those who died during hospitalization or within 10 days following discharge from hospital. All patients were prospectively followed. The primary end point was defined as death …

medicine.medical_specialtybusiness.industryManaged Care ProgramsMyocardial InfarctionPrognosismedicine.diseaseArticleCoronary artery diseasePercutaneous Coronary InterventionInternal medicinemedicineCardiologyHumansManaged careSurvivorsMyocardial infarctionCardiology and Cardiovascular MedicinebusinessCirculation: Cardiovascular Quality and Outcomes
researchProduct

Leishmaniasis among organ transplant recipients.

2008

Leishmaniasis is a rarely reported disease among transplant recipients; however, the number of published cases has quadrupled since the beginning of the 1990s. Most cases have been observed in patients living in countries of the Mediterranean basin. Leishmaniasis is most commonly associated with kidney transplantation (77%), and cases are also recorded among patients undergoing liver, heart, lung, pancreas, and bone marrow transplantation. Visceral leishmaniasis (VL) is the most frequently observed clinical presentation, followed by mucosal leishmaniasis and more rarely cutaneous leishmaniasis. Transplant recipients with VL develop the classic clinical form of the disease, which is a febril…

medicine.medical_specialtybusiness.industryMediterranean RegionIncidence (epidemiology)LeishmaniasisDiseaseOrgan Transplantationmedicine.diseaseOrgan transplantationTransplantationInfectious DiseasesVisceral leishmaniasisCutaneous leishmaniasisInternal medicineImmunologymedicineHumansLeishmaniasis VisceralbusinessLeishmaniasisKidney transplantationThe Lancet. Infectious diseases
researchProduct

Malignant Melanoma S3-Guideline “Diagnosis, Therapy and Follow-up of Melanoma”

2013

This first German evidence-based guideline for cutaneous melanoma was developed under the auspices of the German Dermatological Society (DDG) and the Dermatologic Cooperative Oncology Group (DeCOG) and funded by the German Guideline Program in Oncology. The recommendations are based on a systematic literature search, and on the consensus of 32 medical societies, working groups and patient representatives. This guideline contains recommendations concerning diagnosis, therapy and follow-up of melanoma. The diagnosis of primary melanoma based on clinical features and dermoscopic criteria. It is confirmed by histopathologic examination after complete excision with a small margin. For the stagin…

medicine.medical_specialtybusiness.industryMelanomamedicine.medical_treatmentSentinel lymph nodeIpilimumabDermatologyGuidelinemedicine.diseaseSurgeryMetastasisCutaneous melanomamedicineAdjuvant therapyLymphadenectomyRadiologybusinessmedicine.drugJDDG: Journal der Deutschen Dermatologischen Gesellschaft
researchProduct

Microvascular obstruction in non-STEMI related areas: An uninvited guest in STEMI?

2018

medicine.medical_specialtybusiness.industryMyocardial Infarction030204 cardiovascular system & hematologyCoronary Vessels03 medical and health sciences0302 clinical medicinePercutaneous Coronary InterventionNon stemiInternal medicinemedicineCardiologyHumansST Elevation Myocardial Infarction030212 general & internal medicineCardiology and Cardiovascular MedicinebusinessInternational journal of cardiology
researchProduct

Management of Antiaggregated and Anticoagulated Patients Scheduled for Thoracic Surgery: Recommendations for Venous Thromboprophylaxis

2017

The management of patients under the effect of antiplatelet or anticoagulant agents is a common challenge in thoracic surgery. Their temporary interruption or continuation needs a balanced assessment between the risk of thrombosis (interruption) and bleeding (continuation). Moreover, most patients must receive an anticoagulant for thromboprophylaxis (mainly a low-molecular-weight heparin). So, it is important to have in mind all surgical and anaesthetic implications of these drugs to take the optimal decision in each case.

medicine.medical_specialtybusiness.industrymedicine.drug_classmedicine.medical_treatmentAnticoagulantPercutaneous coronary interventionHeparinmedicine.diseaseThrombosisMechanical heart-valveSurgeryCardiothoracic surgerymedicineStent implantationAnticoagulant AgentIntensive care medicinebusinessmedicine.drug
researchProduct

Impact of admission hyperglycemia on one-year mortality in non-diabetic patients admitted for rescue PCI

2013

medicine.medical_specialtybusiness.industrymedicine.medical_treatmentCardiogenic shockPercutaneous coronary interventionInfarctionmedicine.diseaseIntensive care unitlaw.inventionlawDiabetes mellitusEmergency medicineConventional PCIMedicineMyocardial infarctionMedical emergencyCardiology and Cardiovascular MedicinebusinessNon diabeticEuropean Heart Journal
researchProduct